Other Corporate Information – Page 7

2023-01-09

Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...

2023-01-02

Regulatory

52% Objective Response Rate in pre-planned interim efficacy analysis of mitazalimab combined with mFOLFIRINOX in 1st line metastatic pancrea ...

2023-01-02

Regulatory

The second project aims to develop a bispecific antibody with potential applications in solid tumors Alligator and Orion each to provide val ...

2022-12-22

Data confirm mitazalimab's manageable safety profile via a thorough dose-escalation approach via intravenous administration Pharmacokin ...

2022-12-13

Lund, Sweden, December 13, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives w ...

2022-11-10

Mitazalimab data show the CD40 agonist induces strong immune responses in patients with advanced stage solid tumors and further strengthens ...

2022-11-09

ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody ALG.APV-527 Rapidly Progres ...

2022-11-08

Study to evaluate AC101 (HLX22) in combination with anti-PD-1 antibody serplulimab, trastuzumab and chemotherapy in gastric cancer Phase 2 c ...

2022-11-02

Article shows CD40 x TAA bispecific antibodies can induce enhanced T cell cross-priming superior to monospecific CD40 antibodies using in vi ...